Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00525057 · OUTCOME

Number of Participants With Post-operative Wound Complications

Dalteparin in Preventing DVT in Participants With Cancer · Source last updated 2021-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
4 weeks after surgery

What was measured

Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.

Groups in this outcome

Interventional (Dalteparin, Metastatic)

Received dalteparin 5000 units daily postop, patients with metastatic disease.

Interventional (Dalteparin, Sarcoma)

Received dalteparin 5000 units daily postop, patients with primary sarcomas.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Interventional (Dalteparin, Metastatic)25
Interventional (Dalteparin, Sarcoma)25

Reported measurements

Seroma
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Interventional (Dalteparin, Metastatic)1Not reportedNot reportedNot reportedNot reported
Interventional (Dalteparin, Sarcoma)4Not reportedNot reportedNot reportedNot reported
Wound Infection
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Interventional (Dalteparin, Metastatic)0Not reportedNot reportedNot reportedNot reported
Interventional (Dalteparin, Sarcoma)3Not reportedNot reportedNot reportedNot reported
Wound Dehiscence
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Interventional (Dalteparin, Metastatic)0Not reportedNot reportedNot reportedNot reported
Interventional (Dalteparin, Sarcoma)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        4
    title
    Seroma
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3
    title
    Wound Infection
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    Wound Dehiscence
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    2. group Id
      OG001
      value
      25
    units
    Participants
description
Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.
groups
  1. description
    Received dalteparin 5000 units daily postop, patients with metastatic disease.
    id
    OG000
    title
    Interventional (Dalteparin, Metastatic)
  2. description
    Received dalteparin 5000 units daily postop, patients with primary sarcomas.
    id
    OG001
    title
    Interventional (Dalteparin, Sarcoma)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
4 weeks after surgery
title
Number of Participants With Post-operative Wound Complications
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice